Chemistry:Peptide 021
From HandWiki
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C27H42N6O8 |
| Molar mass | 578.667 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Peptide 021 (Ac-DGGLAG-NH2, P021, GLXC-21260) is a synthetic peptide derivative that is derived from a 4-amino acid active fragment of ciliary neurotrophic factor, which has been substituted with an unnatural adamantane based amino acid residue on the end of the chain. This substitution is highly lipophilic and facilitates transport of the molecule across the blood-brain barrier. It has neurotrophic effects and enhances neurogenesis, and has been investigated for treatment of neurological disorders such as Alzheimer's disease.[1][2][3][4][5][6][7]
See also
- Adamax
References
- ↑ "Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice". FEBS Letters 584 (15): 3359–3365. August 2010. doi:10.1016/j.febslet.2010.06.025. PMID 20600002. Bibcode: 2010FEBSL.584.3359L.
- ↑ "Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound". Neurobiology of Aging 35 (9): 2134–2146. September 2014. doi:10.1016/j.neurobiolaging.2014.02.017. PMID 24702821.
- ↑ "Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease". Neurobiology of Disease 71: 110–130. November 2014. doi:10.1016/j.nbd.2014.07.001. PMID 25046994.
- ↑ "Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome". Scientific Reports 7. April 2017. doi:10.1038/srep45561. PMID 28368015. Bibcode: 2017NatSR...745561K.
- ↑ "Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound". Alzheimer's Research & Therapy 9 (1). June 2017. doi:10.1186/s13195-017-0273-7. PMID 28655344.
- ↑ "Neurotrophic Treatment Initiated During Early Postnatal Development Prevents the Alzheimer-Like Behavior and Synaptic Dysfunction". Journal of Alzheimer's Disease 82 (2): 631–646. 2021. doi:10.3233/JAD-201599. PMID 34057082.
- ↑ "The development of peptide- and oligonucleotide-based drugs to prevent the formation of abnormal tau in tauopathies". Expert Opinion on Drug Discovery 18 (5): 515–526. May 2023. doi:10.1080/17460441.2023.2200245. PMID 37042028.
 |  |
